RxDoctor Payments Data

David Lin, MD

Clinical Cardiac Electrophysiology · Phila, PANPI 1245262542

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (44.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Philips North America LLC at 32.9% of the total. Reporting peaked in 2023 at $15,141 and has fallen 65.9% since, to $5,170 in 2025.

$51,171in general payments, 2019–2025

Across 192 payments — averaging $266.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Philips North America LLC$17K
  • Abbott$14K
  • Kiniksa Pharmaceuticals, Ltd.$8K
  • Boston Scientific$7K
  • Medtronic$4K
  • Terumo Medical Corporation$350
  • plus $1K from 13 others
$127,659in research payments, 2019–2025

Across 15 payments — averaging $8510.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$97K
  • Microport CRM USA Inc$17K
  • Philips North America LLC$11K
  • Abbott$2K

What the payments were for

  • Consulting fees$11,95223%
  • Speaking & faculty fees$22,89445%
  • Travel & lodging$10,46720%
  • Food & beverage$5,85711%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$51,171 in reported general payments places this provider in the 75th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

See all clinical cardiac electrophysiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$198,336
Medicare patients
958
Services billed
2,854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban76$83,804
XareltoRivaroxaban18$17,782
Dofetilide22$7,711
Flecainide Acetate37$1,659
Metoprolol Succinate82$1,392
Amiodarone Hcl15$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$46$17,78218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

Other clinical cardiac electrophysiology in Phila

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →